These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 25596701)

  • 1. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
    Abdel-Rahman O; Fouad M
    Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(8):1275-90. PubMed ID: 25832882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
    Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Merola E; Dal Buono A; Denecke T; Arsenic R; Pape UF; Jann H; Wiedenmann B; Pavel ME
    Pancreas; 2020 Aug; 49(7):912-917. PubMed ID: 32658073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
    Ohmoto A; Morizane C
    Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
    Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
    Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.
    Kidd M; Modlin I; Öberg K
    Nat Rev Clin Oncol; 2016 Nov; 13(11):691-705. PubMed ID: 27273044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Alexandraki KI; Daskalakis K; Tsoli M; Grossman AB; Kaltsas GA
    Trends Endocrinol Metab; 2020 Mar; 31(3):239-255. PubMed ID: 31839442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 20. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.